Aim — to analyze the effect of 6 polymorphic sites of lipoproteinlipase gene (LPL) (rs268, rs285, rs328, rs1801177 rs2083637, rs10096633) on the outcomes in CAD patients undergoing percutaneous coronary interventions (PCI). Material and methods. 84 patients with coronary artery disease undergoing elective PCI were enrolled. Mean age of patients was 59.3±2.1 years. Mean follow-up was 6.2±0.2 years. Analysis was performed depending on the achievement of clinical end points (recurrent angina after PCI, myocardial infarction after PCI, cardiovascular death) which had angiographic confirmation with stent restenosis, progressive coronary atherosclerosis outside the stenting area, or presence of stent thrombosis. Results. Associations of alleles and genotypes of four polymorphisms of LPL gene with development of adverse cardiovascular events (recurrent angina, myocardial infarction after PCI, cardiovascular death) after PCI were identified: 1) LPL rs285. Alleles T: OR=2.68; 95% CI 1.38—5.21. Genotype TT: OR=2.98; 95% CI 1.07—8.26. 2) LPL rs328 (S447X). Alleles G: OR=6.06; 95% CI 1.54—23.8. Genotype CG: OR=7.07; 95% CI 1.7—29.3. 3) LPL rs2083637. Alleles G: OR=2.45 95% CI 1.2—5.01. 4) LPL rs10096633. Alleles T: OR=7.13; 95% CI 2.42—21.0. Genotype CT: OR=5.67; 95% CI 1.71—18.8. There was no association with adverse cardiovascular events after PCI for other polymorphic markers. Conclusion. The effect of lipoproteinlipase gene polymorphism (rs285; rs328 (S447X); rs2083637; rs10096633) on PCI outcomes was established. Variant alleles are accompanied by increased incidence progressive coronary atherosclerotic process outside the stenting zone. In addition, effect of LPL rs285 polymorphism on the incidence of post-PCI restenosis has been established. Accordingly, variant alleles of LPL gene are associated with increased risk of adverse cardiovascular events after PCI (myocardial infarction, recurrent angina and cardiovascular death).